Snipr Biome and US cancer hospital target gut microbes in attempt to eradicate immune therapy side effects

The preclinical collaboration with the US cancer hospital MD Anderson could prove crucial for the biotech company when it raises capital in 2022.

Photo: EY / PR

At Snipr Biome, preparations to break out of its mold have begun.

Even though the company's main focus has been developing treatments for difficult-to-treat infections, Snipr is now setting its sights on an entirely new area by partnering with the prestigious Texan cancer hospital MD Anderson. Snipr is now going to help the improve side effects of immune therapy.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs